Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
SAN FRANCISCO, May 08, 2018 -- Nurix, Inc., a private drug discovery company, today announced the appointment of Dr. Nancy Pryer as the company’s chief development officer. Dr. Pryer will join Nurix’s executive management team to lead the company’s preclinical, translational and clinical drug development efforts.
“We are delighted to welcome Dr. Pryer to Nurix,” said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. “Her extraordinary depth of experience in oncology and drug development broadly will provide great value to Nurix as we advance our breakthrough science into human clinical studies.”
Dr. Pryer joins Nurix from BioMarin Pharmaceutical, where she served as vice president of translational sciences. In that role, she led the company’s efforts in biomarker discovery, bioanalytics, immunogenicity assessment and clinical pharmacology. Prior to joining BioMarin, Dr. Pryer held leadership roles in oncology drug discovery and translational development at Novartis Institutes for Biomedical Research, Raven, SUGEN and Onyx Pharmaceuticals. Dr. Pryer received her Ph.D. in biology from the University of North Carolina, Chapel Hill, and completed post-doctoral work in the lab of Dr. Randy Schekman at the University of California, Berkeley.
“This is an exciting time in the field of protein homeostasis and targeted protein degradation, as years of effort are yielding novel candidate therapeutics for oncology and other unmet medical needs,” said Dr. Pryer. “Throughout my career I’ve been passionate about evaluating drug mechanism of action to develop new therapies for select patient populations. I look forward to working with Arthur and the Nurix team to apply these translational medicine approaches as we move the Nurix pipeline through IND-enabling studies and into the clinic.”
About Nurix
Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurix-inc.com.
Media Contact
Sara Zelkovic
LifeSci Public Relations
[email protected]
